Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

Summary

This phase II trial studies the effect of nivolumab and ADI-PEG 20 before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ADI-PEG 20 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. Giving nivolumab and ADI-PEG 20 before surgery may help control liver cancer.

Timeline

Start

2022-04-13

Primary completion

2023-02-10

Completion

2023-02-10

Drugs

Indications